MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

Search

Heron Therapeutics Inc

Затворен

СекторЗдравеопазване

2 -0.5

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2

Максимум

2.04

Ключови измерители

By Trading Economics

Приходи

-1M

2.6M

Продажби

-1.9M

39M

Марж на печалбата

6.773

Служители

122

EBITDA

-5M

3.7M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+209.41% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-28M

323M

Предишно отваряне

2.5

Предишно затваряне

2

Настроения в новините

By Acuity

25%

75%

64 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Heron Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.07.2025 г., 23:34 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17.07.2025 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17.07.2025 г., 21:04 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17.07.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17.07.2025 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17.07.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17.07.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17.07.2025 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17.07.2025 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17.07.2025 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17.07.2025 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17.07.2025 г., 22:30 ч. UTC

Пазарно говорене
Печалби

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17.07.2025 г., 22:20 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

17.07.2025 г., 22:20 ч. UTC

Пазарно говорене
Печалби

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17.07.2025 г., 22:04 ч. UTC

Пазарно говорене
Печалби

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17.07.2025 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17.07.2025 г., 21:58 ч. UTC

Пазарно говорене
Печалби

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17.07.2025 г., 21:57 ч. UTC

Печалби

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17.07.2025 г., 21:47 ч. UTC

Печалби

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17.07.2025 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17.07.2025 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17.07.2025 г., 21:05 ч. UTC

Печалби

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17.07.2025 г., 21:04 ч. UTC

Придобивния, сливания и поглъщания

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17.07.2025 г., 21:02 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17.07.2025 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

17.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Heron Therapeutics Inc Прогноза

Ценова цел

By TipRanks

209.41% нагоре

12-месечна прогноза

Среден 6.25 USD  209.41%

Висок 9 USD

Нисък 4 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Heron Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

2.0001 / 2.42Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

64 / 376 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.